Monitoring Warfarin Therapy

Introduction to Warfarin Monitoring

The American College of Cardiology recommends using the International Normalized Ratio (INR) as the primary monitoring parameter for patients on warfarin, with a therapeutic target of 2.0-3.0 for most indications, which typically corresponds to a PT of approximately 1.5-2.5 times the control value 1, 2, 3
The American Geriatrics Society recommends that the INR be used to standardize PT results across laboratories and eliminate variability 2

The American College of Cardiology and the American Geriatrics Society recommend the following target INR ranges: 2.0-3.0 for atrial fibrillation with stroke risk factors, venous thromboembolism, rheumatic heart disease, and bioprosthetic heart valves (first 3 months) 1, 2, 3
The American Geriatrics Society recommends a higher intensity range of 2.5-3.5 for mechanical prosthetic heart valves, recurrent systemic embolism despite adequate anticoagulation, and patients at extremely high risk of stroke 2, 3, 4

The American College of Cardiology recommends checking INR daily until therapeutic range is reached and sustained for 2 consecutive days, then 2-3 times weekly for 1-2 weeks, and then weekly for 1 month 1, 2, 3
Once stable, INR can be checked as infrequently as every 4 weeks, but frequent monitoring should be resumed during medication changes, dietary changes, illness, or any bleeding 2, 3

The American College of Cardiology warns against relying on PT values alone for warfarin monitoring, as different thromboplastin reagents produce vastly different PT values for the same level of anticoagulation 1
Concurrent medications, such as amiodarone, can significantly affect warfarin response and require close INR monitoring, according to the American Academy of Family Physicians 5

The American College of Cardiology and the American Geriatrics Society state that subtherapeutic anticoagulation (INR <2.0) significantly increases the risk of thromboembolism and provides inadequate protection against stroke and clot formation 3, 4
Supratherapeutic anticoagulation (INR >4.0) increases the risk of bleeding, and the American College of Cardiology recommends reducing or omitting the next dose, resuming at a lower dose when INR approaches therapeutic range, and considering oral vitamin K for INR 5.0-9.0 without bleeding 3, 4